Formerly dba Photozyne and having strong ties to University of Buffalo, POP Biotechnologies LLC is developing biomedical solutions designed to harness nanotechnologies. The firm has has developed a vaccine adjuvant - designated SNAP, an abbreviation for Spontaneous Nanoliposome-Antigen Particleization. Often used to enhance the efficacy of vaccines and drug treatments, Adjuvants are immunological agents. The technology can make existing vaccine responses more powerful and longer-lasting offering the potential to create vaccines for diseases that so far have evaded a vaccination. Tackling realiing the potential of the revolutionary porphyrin-phospholipid (POP) liposome technology developed by one of the frm's founders, POP BIO is also working on a light-based chemotherapy treatment that kills cancer cells while causing only limited harm to the tissue around them. NP-01, is a light-activated cancer therapy incorporating the oncolytic drug doxorubicin in a unique photosensitive carrier that provides targeted and enhanced release of drug to tumors upon laser light exposure. NP-01 is designed to address solid tumors which lack effective treatment options, such as cutaneous metastatic breast cancer (CMBC), liver cancer, and pancreatic cancer, by combining the potency of a widely-utilized chemotherapy with photodynamically enhanced and localized release.
